Qfitlia™
(fitusiran) injection
50 mg/0.5 mL

YOUR GUIDE TO STARTING QFITLIA™



Patient portrayal and hypothetical scenario.

Rethink what's possible

This resource and others linked within are not intended to provide medical advice. Speak to your doctor if you have questions.

INDICATION

Qfitlia™ (fitusiran) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B with or without Factor VIII or IX inhibitors.

It is not known if Qfitlia is safe and effective in children younger than 12 years of age.

IMPORTANT SAFETY INFORMATION

Qfitlia can cause SERIOUS SIDE EFFECTS, including:

- **Abnormal blood clotting (thrombotic events):** Serious blood clots have occurred in people treated with Qfitlia. Qfitlia can cause blood clots to form in the blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin (AT) blood level is persistently less than 15% or if you have certain other conditions. Your healthcare provider (HCP) will check your AT blood levels before and during treatment with Qfitlia
- **Gallbladder disease:** Qfitlia can cause gallstones and inflammation of your gallbladder, which might require surgery to remove your gallbladder. Tell your HCP right away if you develop stomach pain, indigestion, nausea, or vomiting. Your HCP may temporarily or permanently stop Qfitlia if you develop any of these symptoms

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

WELCOME TO THE START OF YOUR JOURNEY WITH QFITLIA™

Consistent protection with as few as 6 injections a year*

Qfitlia prophylaxis helps your blood's ability to clot by lowering a protein called antithrombin.



Patient portrayal.

* In the clinical study of 227 people, ~67% of people with hemophilia took Qfitlia every other month, and ~19% took it monthly.

Starting a different treatment can be exciting and you may have questions as you get used to a new routine

This guide provides you with the information you need to start using Qfitlia, including:

1. **Key features and benefits**
2. **Getting the right dose for you**
3. **Mastering the injection**
4. **Following a bleed management plan**
5. **Understanding possible side effects**

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about Qfitlia?

Qfitlia helps your blood form clots. Do not stop using Qfitlia without talking to your HCP. If you miss doses or stop using Qfitlia, you may no longer be protected against bleeding.

Use of a clotting factor concentrate (CFC) or bypassing agent (BPA) to help protect against bleeding must be stopped within 7 days after your first dose of Qfitlia.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

KEY FEATURES AND BENEFITS

Qfitlia™ is an antithrombin-lowering agent for people aged 12 years and older with hemophilia A or B, with or without inhibitors

As few as 6 injections a year*

- The starting dose of Qfitlia is 50 mg, administered once every two months
- Your doctor will monitor your antithrombin levels via a blood test before starting treatment and again during Months 1, 3, 5, and 6, adjusting the dose as needed. This testing cycle will restart if a dose adjustment is made. Once your maintenance dose is determined, your doctor will monitor antithrombin via a blood test on a yearly basis
- Your doctor will monitor your liver enzymes via a blood test before starting treatment, monthly for at least 6 months after starting treatment, and monthly for at least 6 months after a dose increase

Easy-to-use prefilled pen†



- Injected just below the skin (subcutaneously)
- No mixing needed
- No weight-based dosing

No refrigeration for up to 3 months

- Qfitlia Prefilled Pen may be stored at room temperature between 59 °F to 86 °F (15 °C to 30 °C) for a single period of up to 3 months within the expiration date printed on the label
- Allows for ease of travel

Patient portrayal.

* In the clinical study of 227 people, ~67% of people with hemophilia took Qfitlia every other month, and ~19% took it monthly.
† Prefilled pen administration for the 50 mg dose. Vial and syringe administration for the 10 mg and 20 mg dose.

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about Qfitlia? (cont'd)

Your HCP may prescribe on-demand CFC or BPA if you bleed during treatment with Qfitlia. **Carefully follow your HCP's instructions regarding when to use on-demand treatment with CFC or BPA, including the prescribed dose and timing of the CFC or BPA.**

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

GETTING THE RIGHT DOSE FOR YOU

Your doctor will run blood tests to measure your antithrombin levels and may adjust your dose of Qfitlia™ to keep them within a certain range. **The goal is to reach a maintenance dose.**

Starting dose

STEP 1

First month

1 antithrombin test before starting to measure antithrombin activity and confirm eligibility

50 mg prefilled pen

- Factor or bypassing agent (BPA) prophylaxis must be discontinued 7 days after your first dose of Qfitlia

Find your right dose

STEP 2

1–6+ months

4 antithrombin tests in total after starting or adjusting dose

Dosed every 2 months or every month

- If your antithrombin levels are not within range, your doctor may adjust your dose or change the frequency to once a month
- During at least your first 6 months of treatment, your doctor will run blood tests to measure your antithrombin level at Months 1, 3, 5, and 6, to decide if a dose adjustment is needed. This testing cycle will restart if a dose adjustment is made

Maintenance dose

STEP 3

6+ months

6 or 12 injections per year

1 antithrombin test per year thereafter

What is antithrombin?

Antithrombin is a protein that prevents blood from clotting. Keeping your antithrombin level within the target range of 15% and 35% helps avoid too much clotting or bleeding. As Qfitlia lowers antithrombin levels, it's important to have yours checked regularly.

Find out more about how Qfitlia works

In the clinical study, of 227 people:

- **~35%** required no dose adjustments from the recommended starting dose
- **~67%** were dosed every other month and **~19%** were dosed once a month

Work with your doctor to schedule your antithrombin tests to ensure you have the right dose. Your doctor will let you know when to take your next dose and how much Qfitlia to inject. Your doctor will monitor your liver function using blood tests before starting and for at least 6 months after starting Qfitlia.

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about Qfitlia? (cont'd)

Get medical help right away if you get any of these signs or symptoms of blood clots during or after treatment with Qfitlia:

- Swelling, pain, or redness in arms or legs
- Coughing up blood
- Shortness of breath
- Severe chest pain or tightness of the chest
- Fast heart rate
- Feeling faint or passing out

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

MASTERING THE INJECTION

Qfitlia™ is injected just **below the skin** (subcutaneously) using a prefilled pen or vial and syringe, depending on the dose your doctor prescribes. No mixing or reconstitution is needed.

Prefilled pen

Delivers **50 mg dose** of Qfitlia in a small volume injection (0.5 mL).

Vial and syringe

Delivers **20 mg** or **10 mg dose** of Qfitlia in a small volume injection (0.2 mL or 0.1 mL).

Support is available to help you master the injection

Always contact your healthcare provider for injection training and any questions.

In addition to support provided by your healthcare provider, explore supplemental resources.

Watch the injection tutorial video

HemAssist™ Patient Support from Sanofi provides supplemental injection training and more information throughout your journey with Qfitlia
Learn more

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about Qfitlia? (cont'd)

Get medical help right away if you get any of these signs or symptoms of blood clots during or after treatment with Qfitlia: (cont'd)

- Severe or persistent headache
- Difficulty speaking or understanding language
- Feeling confused
- Numbness or weakness in your face, arms, or legs
- Sudden loss or changes in your vision, eye pain, or swelling

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

FOLLOWING A BLEED MANAGEMENT PLAN

Qfitlia™ is a prophylactic treatment only. It cannot be used to treat a breakthrough bleed. In case of a bleed while using Qfitlia, on-demand treatment is required.

How to get a bleed management plan

Before starting Qfitlia, your doctor will create a bleed management plan with you in case of a breakthrough bleed. Carefully follow your healthcare provider's instructions on when to use on-demand treatment with clotting factor concentrate or bypassing agent, the prescribed dose, and schedule.

Qfitlia works differently from other hemophilia treatments. **Using it with on-demand treatment increases the potential for abnormal blood clotting known as a thrombotic event or thrombosis**. As a result, lower and less frequent doses of on-demand treatment should be used to treat breakthrough bleeds.

Risk of thrombosis

Serious blood clots have happened in people treated with Qfitlia.

Qfitlia can cause blood clots to form in blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin blood level is persistently less than 15% or if you have certain other conditions.

Thrombotic events were reported in 4 out of 286 (1.4%) trial participants receiving Qfitlia prophylaxis in the extension study for Qfitlia, in which dosing was based on antithrombin levels.

All 4 people had multiple risk factors and/or deviated from the bleed management guidelines, which may have contributed to their increased risk of thrombosis.

It is critical to follow your bleed management plan should a breakthrough bleed occur during treatment with Qfitlia.

Find out more on why and how to plan for a breakthrough bleed

Prefer keeping your plan on an emergency card or your phone?

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of Qfitlia?

- **Qfitlia can cause other serious side effects, including an increase in your blood liver enzymes.** Your HCP will do blood tests to check your liver function before and during treatment with Qfitlia
- **The most common side effects of Qfitlia include** viral infection, common cold symptoms, and bacterial infection

These are not all the possible side effects of Qfitlia.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

UNDERSTANDING POSSIBLE SIDE EFFECTS

As with all medicines, Qfitlia™ may cause serious side effects.

Most common adverse reactions in people treated with antithrombin-based dosing regimen	Percent out of 286 people total
Viral infection	29%
Common cold symptoms	26%
Bacterial infection	11%
Liver injury/Increased blood liver enzymes	8%
Joint pain	8%
Prothrombin fragment 1.2 increased (increased clotting activity)	7%
Injection site reaction*	6%
Headache	5%
Cough	5%

Your doctor will closely monitor you for certain adverse reactions:

- **Abnormal blood clotting (thrombotic events):** Serious blood clots have occurred in people treated with Qfitlia. Qfitlia can cause blood clots to form in blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin blood level is persistently less than 15% or if you have certain other conditions. Get medical help right away if you get any of these signs or symptoms of blood clots during or after treatment with Qfitlia: swelling, pain, or redness in arms or legs; coughing up blood; shortness of breath; severe chest pain or tightness of the chest; fast heart rate; feeling faint or passing out; severe or persistent headache; difficulty speaking or understanding language; feeling confused; numbness or weakness in your face, arms, or legs; sudden loss or changes in your vision, eye pain, or swelling. Your doctor may modify your dose based on your antithrombin activity to reduce your chance of blood clots
- **Gallbladder disease:** Qfitlia can cause gallstones (cholelithiasis) and inflammation of your gallbladder (cholecystitis), which might require surgery to remove your gallbladder. Tell your healthcare provider right away if you develop stomach (abdomen) pain, indigestion, nausea or vomiting. Your healthcare provider may temporarily or permanently stop your treatment with Qfitlia if you develop any of these symptoms
- **Liver problems:** Qfitlia can cause an increase in your blood liver enzymes. Your healthcare provider will do blood tests to check your liver function before starting treatment, monthly for at least 6 months after starting treatment, and monthly for at least 6 months after a dose increase. Liver testing will continue periodically thereafter

* Redness, tenderness, pain, swelling, warmth, bruising, bleeding, skin changes, rash, or itching at the site of injection.

IMPORTANT SAFETY INFORMATION (CONT'D)

What should I tell my HCP before using Qfitlia?

- **Tell your HCP about all of your medical conditions,** including if you have liver problems, a history of gallbladder disease, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

INDICATION

Qfitlia™ (fitusiran) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B with or without Factor VIII or IX inhibitors.

It is not known if Qfitlia is safe and effective in children younger than 12 years of age.

IMPORTANT SAFETY INFORMATION

Qfitlia can cause SERIOUS SIDE EFFECTS, including:

- **Abnormal blood clotting (thrombotic events):** Serious blood clots have occurred in people treated with Qfitlia. Qfitlia can cause blood clots to form in the blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin (AT) blood level is persistently less than 15% or if you have certain other conditions. Your healthcare provider (HCP) will check your AT blood levels before and during treatment with Qfitlia
- **Gallbladder disease:** Qfitlia can cause gallstones and inflammation of your gallbladder, which might require surgery to remove your gallbladder. Tell your HCP right away if you develop stomach pain, indigestion, nausea, or vomiting. Your HCP may temporarily or permanently stop Qfitlia if you develop any of these symptoms

What is the most important information I should know about Qfitlia?

Qfitlia helps your blood form clots. Do not stop using Qfitlia without talking to your HCP. If you miss doses or stop using Qfitlia, you may no longer be protected against bleeding.

Use of a clotting factor concentrate (CFC) or bypassing agent (BPA) to help protect against bleeding must be stopped within 7 days after your first dose of Qfitlia.

Your HCP may prescribe on-demand CFC or BPA if you bleed during treatment with Qfitlia. **Carefully follow your HCP's instructions regarding when to use on-demand treatment with CFC or BPA, including the prescribed dose and timing of the CFC or BPA.**

Get medical help right away if you get any of these signs or symptoms of blood clots during or after treatment with Qfitlia:

- Swelling, pain, or redness in arms or legs
- Coughing up blood
- Shortness of breath
- Severe chest pain or tightness of the chest
- Fast heart rate
- Feeling faint or passing out
- Severe or persistent headache
- Difficulty speaking or understanding language
- Feeling confused
- Numbness or weakness in your face, arms, or legs
- Sudden loss or changes in your vision, eye pain, or swelling

What are the possible side effects of Qfitlia?

- **Qfitlia can cause other serious side effects, including an increase in your blood liver enzymes.** Your HCP will do blood tests to check your liver function before and during treatment with Qfitlia
- **The most common side effects of Qfitlia include** viral infection, common cold symptoms, and bacterial infection

These are not all the possible side effects of Qfitlia.

What should I tell my HCP before using Qfitlia?

- **Tell your HCP about all of your medical conditions**, including if you have liver problems, a history of gallbladder disease, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed
- **Females who are able to become pregnant:** Hormonal birth control may increase your risk of blood clots if used during treatment with Qfitlia. Talk to your HCP about effective forms of non-hormonal birth control you can use before starting and during treatment with Qfitlia
- **Tell your HCP about all of the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements

Please see full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

Qfitlia™ (fitusiran) injection 50 mg/0.5 mL

YOUR JOURNEY WITH QFITLIA™ STARTS HERE

with support behind you every step of the way

Connect with HemAssist™ Patient Support from Sanofi

After your doctor prescribes Qfitlia for you, HemAssist™ supports you with access to Qfitlia, financial assistance, and education throughout your journey with Qfitlia.

Explore the website for Qfitlia

Download helpful resources to support every step of your journey with Qfitlia.

This resource and others linked within are not intended to provide medical advice. Speak to your doctor if you have questions.

INDICATION

Qfitlia™ (fitusiran) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B with or without Factor VIII or IX inhibitors.

It is not known if Qfitlia is safe and effective in children younger than 12 years of age.

IMPORTANT SAFETY INFORMATION

Qfitlia can cause SERIOUS SIDE EFFECTS, including:

- **Abnormal blood clotting (thrombotic events):** Serious blood clots have occurred in people treated with Qfitlia. Qfitlia can cause blood clots to form in the blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin (AT) blood level is persistently less than 15% or if you have certain other conditions. Your healthcare provider (HCP) will check your AT blood levels before and during treatment with Qfitlia
- **Gallbladder disease:** Qfitlia can cause gallstones and inflammation of your gallbladder, which might require surgery to remove your gallbladder. Tell your HCP right away if you develop stomach pain, indigestion, nausea, or vomiting. Your HCP may temporarily or permanently stop Qfitlia if you develop any of these symptoms

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including SERIOUS SIDE EFFECTS, and Medication Guide.

sanofi

MAT-US-2409946-v1.0-03/2025